Use of a T cell interferon gamma release assay in the investigation for suspected active tuberculosis in a low prevalence area

Niclas Winqvist*1,2, Per Björkman1, Ann Norén1 and Håkan Miörner3

Address: 1Infectious Disease Research Unit, Department of Clinical Sciences, Lund University, Malmö University Hospital, Malmö, Sweden, 2Regional department of Infectious Disease Control and prevention, Malmö, Sweden and 3Medical microbiology, Department of laboratory medicine, Lund University, Lund, Sweden

Email: Niclas Winqvist* - Niclas.Winqvist@skane.se; Per Björkman - Per.Bjorkman@med.lu.se; Ann Norén - Ann.Noren@skane.se; Håkan Miörner - Hakan.Miorner@skane.se

* Corresponding author

Abstract

**Background:** In settings with low background prevalence of tuberculosis (TB) infection, interferon-γ release assays (IGRA) could be useful for diagnosing active TB. This study aims to evaluate the performance of QuantiFERON®-TB Gold (QFT-G) in the investigation for suspected active TB, with particular attention to patients originating in high-incidence countries. Furthermore, factors associated with QFT-G results in patients with active TB were assessed.

**Methods:** From patients investigated for clinically suspected active TB, blood was obtained for QFT-G testing, in addition to routine investigations. Positive (PPV) and negative (NPV) predictive values for QFT-G were calculated, comparing patients with confirmed TB and those with other final diagnoses. QFT-G results in TB patients originating from countries with intermediate or high TB incidence were compared with QFT-G results from a control group of recently arrived asymptomatic immigrants from high-incidence countries. Factors associated with QFT-G outcome in patients with confirmed TB were assessed.

**Results:** Among 141 patients, 41/70 (58.6%) with confirmed TB had a positive QFT-G test, compared to 16/71 (22.6%) patients with other final diagnoses, resulting in overall PPV of 71.9% and NPV of 67.6%. For patients with pulmonary disease, PPV and NPV were 61.1% and 67.7%, respectively, and 90.5% and 66.7% for subjects with extrapulmonary manifestations. Comparing patients from high-incidence countries with controls yielded a PPV for active TB of 76.7%, and a NPV of 82.7%. Patients with confirmed TB and positive QFT-G results were characterized by a lower median peripheral white blood cell count (5.9 × 10^9/L vs. 8.8 × 10^9/L; P < 0.001) and a higher median body mass index (22.7 vs. 20.7; P = 0.043) as compared to QFT-G-negative TB patients.

**Conclusion:** The overall PPV and NPV of QFT-G for identifying active TB were unsatisfactory, especially for pulmonary disease. Thus, the usefulness of QFT-G for this purpose is questionable. However, a high PPV was observed for extrapulmonary TB and QFT-G might be considered in the diagnostic process in this situation. The PPV and NPV for identifying active TB among persons originating from regions with high-and intermediate TB incidence was similar to that observed in subjects originating in the low-incidence region.
Background

Even in low prevalence regions, TB is a common differential diagnosis in infectious disease practice, and different manifestations of TB may be encountered in all medical disciplines. Whereas most cases of pulmonary tuberculosis can be easily identified by detection of bacteria in airway secretions, the diagnosis of extrapulmonary TB is often difficult to establish. Recently, new diagnostic kits for tuberculosis infection, known as interferon-gamma release assays (IGRA:s), have become commercially available. T-SPOT®. TB (Oxford Immunotec Ltd.) is an assay that enumerates TB specific T-lymphocytes by Elispot technique [1], whereas QuantiFERON®-TB and QuantiFERON®-TB Gold (QFT-G; Cellestis Ltd.), are based on ELISA-techniques that measure γ-interferon released by TB specific T-lymphocytes [2]. Both of these tests appear to have higher specificity than the tuberculin skin test (TST) for TB infection [3-6], but the absence of a definite method to diagnose latent TB infection makes direct comparison between diagnostic methods impossible. In low-prevalence regions, TST is of limited value for detection of TB infection, since a high proportion of reactive skin tests have other aetiologies than TB [7], such as recent BCG vaccination or exposure to environmental mycobacteria. In addition to low specificity, the use of TST as a screening tool in patients with suspected active TB is hampered by high rates of false negative reactions in patients with active TB, especially in case of underlying immunodeficiency [8,9]. In the near future IGRA:s may even replace TST as a test for diagnosing latent TB. However, at present their role in the diagnostic process for suspected active infection remains uncertain.

Like TST, IGRA:s cannot differentiate between active and latent TB. A number of studies examining IGRA results in peripheral blood from patients with active TB has been published, and have found surprisingly low sensitivity [10-13]. Thus, their role in diagnosing active TB remains uncertain. However, promising results have recently been published with IGRA testing performed on mononuclear cells obtained from the site of infection e.g. from broncho-alveolar lavage [14].

Sweden has a low incidence of TB (5.5 per 100 000 inhabitants in 2007) [15]. In this setting with a low background prevalence of latent TB, IGRA tests could be useful in the initial diagnostic process in patients with suspected TB [16]. During the last decades, clusters of TB have been observed in large urban centres [16,17]. Considering the epidemiological situation in many industrialized countries with a disproportionate fraction of TB cases occurring in immigrants from high-incidence countries, the ability of new diagnostic methods to detect patients with active or latent TB in immigrant populations is of great importance.

The principal objective of this study was to define the usefulness of QFT-G in the diagnostic procedure for suspected active tuberculosis among patients in Southern Sweden by calculating PPV and NPV for QFT-G. In order to assess the performance among persons originating from high-prevalence areas, a group of healthy recently arrived immigrants from such countries were compared to those in patients with similar origin. We also aimed to identify factors associated with QFT-G results in patients with confirmed active TB.

Methods

Study population

This study was conducted in Malmö and Lund in Southern Sweden (population ca 400 000). In this area, about 40 cases of TB are reported annually. Study subjects belonged to two categories: case patients with suspected tuberculosis, and healthy immigrants who had recently arrived in Sweden from countries with a high prevalence of TB.

Patients were recruited consecutively from the departments of infectious and pulmonary diseases in the university hospitals in Malmö and Lund between September 2004 and February 2007. Inclusion criteria were: age over 15 years, written informed consent, and ongoing investigation for symptoms or signs for which TB was considered as a differential diagnosis. Medical investigation typically included microbiological testing from affected organs, radiological investigations and histopathological studies, according to disease manifestations. Patients were excluded if TB treatment had been initiated more than 1 week prior to study entry, or if TB investigations were done as part of a routine diagnostic package with no definite clinical suspicion of TB (e.g. patients undergoing bronchoscopy for investigation of pulmonary lesions, in which TB cultures are routinely obtained). For patients with suspected TB, an interview and record-based questionnaire covering general medical history, risk factors for exposure to TB and details concerning ongoing disease and results of medical investigations was completed by either a physician or a specialized nurse. TST was recommended, but not required, for study inclusion.

Since around 80 percent of all TB cases in the study area occur among immigrants from countries with high or intermediate TB incidence [18] we chose to compare results in immigrant patients with active TB with those in healthy subjects with similar geographical origin. A control group of recently (within 7 months) arrived immigrants, aged over 15 years and without significant medical history, were recruited from a primary care centre performing health examinations, which are offered to all immigrants arriving in Sweden. Recruitment of immigrants was performed between March 2006 and Septem-
influence the diagnostic procedure.

The results of the QFT-G tests were not available to the defined as indeterminate.

minus the negative control was < 0.5 the result was control for the result to be valid. If the mitogen response had to be at least half of the concentration of the negative control (kindly provided by Karin Weldingh; Statens Serum Institut, Copenhagen, Denmark) and purified protein derivative (PPD; Art. No 2390; Statens Serum Institut) were used for incubation experiments. After 16 – 24 hours of incubation at 37°C in 5% CO2, supernatants were collected and frozen at -20°C until analysis. Concentrations of interferon-gamma (INF-γ) in 50 μl of plasma from whole-blood stimulated with the antigens, mitogen (positive control) or saline (negative control) were measured using the ELISA kit provided with the QFT-G package. A positive result was defined as a concentration of INF-γ of ≥0.35 IU/mL after subtraction of the INF-γ concentration from the negative control in at least 1 of the specific antigens ESAT-6, CFP-10 or TB7.7. The INF-γ concentration in the antigen stimulated wells had to be at least half of the concentration of the negative control for the result to be valid. If the mitogen response minus the negative control was < 0.5 the result was defined as indeterminate.

The results of the QFT-G tests were not available to the physicians in charge of the patients, and thus did not influence the diagnostic procedure.

**QuantiFERON-TB® Gold test**

Whole blood was collected in heparin-containing tubes for the QuantiFERON®-TB Gold test (Cellestis Ltd, Victoria, Australia). Samples were transported to the laboratory within 4 hours and incubation with antigens was initiated within 7 hours after collection. Antigens provided in the QFT-G test kit were the 6 kDa early secreted antigenic target (ESAT-6) and culture filtrate protein 10 (CFP-10); in addition to these, TB7.7 (kindly provided by Karin Weldingh; Statens Serum Institut, Copenhagen, Denmark) and purified protein derivative (PPD; Art. No 2390; Statens Serum Institut) were used for incubation experiments. After 16 – 24 hours of incubation at 37°C in 5% CO2, supernatants were collected and frozen at -20°C until analysis. Concentrations of interferon-gamma (INF-γ) in 50 μl of plasma from whole-blood stimulated with the antigens, mitogen (positive control) or saline (negative control) were measured using the ELISA kit provided with the QFT-G package. A positive result was defined as a concentration of INF-γ of ≥0.35 IU/mL after subtraction of the INF-γ concentration from the negative control in at least 1 of the specific antigens ESAT-6, CFP-10 or TB7.7. The INF-γ concentration in the antigen stimulated wells had to be at least half of the concentration of the negative control for the result to be valid. If the mitogen response minus the negative control was < 0.5 the result was defined as indeterminate.

The results of the QFT-G tests were not available to the physicians in charge of the patients, and thus did not influence the diagnostic procedure.

**Tuberculin skin test**

TST was done by intradermal injection of 0.1 ml (2 TU) PPD (RT23; Statens Serum Institut, Copenhagen, Denmark). Skin induration was measured after 72 hours and was interpreted according to the recommendations by the manufacturer. In most cases TST was done prior to QFT-G or at the same time.

**Statistical methods**

Positive (PPV) and negative (NPV) predictive values of the QFT-G test among patients were calculated using a final TB diagnosis as true positive and other final diagnoses as true negative outcome. To facilitate comparisons with other studies, calculations of sensitivity and specificity for the diagnosis of active TB were also performed. McNemar test was used to test for overall accuracy. Patients with indeterminate QFT-G results were excluded from the analysis.

For dichotomous variables an odds ratio was calculated. Differences in odds ratio with a p-value <.05 was considered significant. Odds ratios were defined as the exponent of the estimated beta for dichotomous variables. When comparing means for continuous variables the Student’s t-test was used for variables with normal distribution. For other variables the Mann-Whitney’s non-parametric test was used.

The study procedure was approved by the ethical vetting board, Lund University, Sweden.

**Results**

**Patients with suspected tuberculosis**

In 70 of 141 patients, the diagnosis of TB was established, whereas 71 patients received another final diagnosis (most frequent were bacterial pneumonia [17], cancer [5], and other respiratory diseases [4]). Characteristics of the patients are shown in Table 1. TB was bacteriologically confirmed either by culture, microscopy or polymerase chain reaction (PCR) in 61 patients (87%); in the remaining 9 patients, diagnosis was based on clinical criteria, supported by radiological and/or histopathological findings, and response to anti-tuberculosis therapy.

Patients originating from countries with an estimated TB-incidence of more than 20 new cases per 100 000 inhabitants according to the World Health Organization (WHO)[20] were significantly more likely to get a TB diagnosis compared to those from low incidence countries (52/75 vs. 18/66; P < 0.001). Patients with TB were also younger than those with another final diagnosis (median age 38 years vs. 58; P < 0.001). Other parameters analyzed did not differ significantly between patients with confirmed TB and non-TB cases.

**QuantiFERON-TB® Gold results in patients with suspected tuberculosis**

Results of QFT-G for respective patient categories are presented in Table 2. Ten subjects had indeterminate QFT-G
results; these patients did not differ significantly from those with a positive or negative QFT-G result with regard to any of the parameters tested.

For the whole group of patients, the PPV and NPV of QFT-G was 71.9% and 67.6%, respectively. The sensitivity and specificity for QFT-G was 63.1% and 75.8% respectively (McNemar test for overall accuracy: $P = 0.268$).

Among 104 patients with pulmonary disease manifestations, QFT-G was positive in 22 of 44 TB-cases and in 14 out of 60 non-TB patients, (PPV 61.1%, NPV 67.7%; Table 2). In this subgroup the sensitivity was 52.4% and the specificity 75.0% (McNemar test: $P = 0.392$).

Thirty-seven patients had suspected extrapulmonary TB. Out of these, 21 had a positive QFT-G test, 12 had a negative test and in 4 subjects the QFT-G result was indeterminate (Table 2). Two of the 21 QFT-G-positive subjects with suspected extrapulmonary TB received a final diagnosis other than TB. The PPV and NPV of QFT-G in subjects with suspected extrapulmonary TB was 90.5% and 66.7% and sensitivity and specificity was 82.6% and 80.0% respectively (McNemar test: $P = 0.687$).

In the subgroup of patients originating from countries with high or intermediate TB incidence, PPV and NPV were 78.6% and 46.7% respectively (pulmonary and extrapulmonary disease manifestations combined).

| Table 1: Characteristics of patients investigated for suspected active tuberculosis, and controls |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Tuberculosis   | Other final diagnoses | Controls |
|----------------|----------------------|----------|
| Women (%)      | 40 (57.1)            | 35 (49.3) | 35 (35.7) |
| Median age (years) | 38                  | 58       | 32 |
| Median BMI     | 22                   | 23       | 23 |
| Origin from country with high or intermediate TB-incidence* (%) | 52 (74.3) | 23 (32.4) | 98 (100) |
| Immune supression** (%) | 19 (27.1) | 28 (39.4) | 0 (0.0) |
| Affected organ |
| Lung (%)       | 44 (62.9)            | 60 (84.5) | 67 (68.4) |
| Pleura (%)     | 3 (4.3)              | 1 (1.4)   | 1 (1.0) |
| Mediastinal lymph node (%) | 1 (1.4) | 2 (2.8) | 1 (1.0) |
| Peripheral lymph node (%) | 10 (14.3) | 1 (1.4) | 1 (1.0) |
| Joint/skeleto-muscular (%) | 3 (4.3) | 3 (4.3) | 3 (3.1) |
| Skin/soft tissue (%) | 2 (2.8) | 1 (1.4) | 1 (1.0) |
| Gastrointestinal/abdominal (%) | 4 (5.7) | 0 (0.0) | 0 (0.0) |
| Urogenital (%) | 0 (0.0)              | 1 (1.4)   | 1 (1.0) |
| Multiple locations (%) | 3 (4.3) | 2 (2.8) | 2 (2.1) |

TB: Tuberculosis; BMI: Body Mass Index
* Defined as ≥20 cases/100 000 inhabitants
** HIV-infection (n = 6), immunosuppressive treatment (n = 18), diabetes (n = 9), alcohol or drug abuse (n = 9), cancer (n = 4), Mb Down (n = 1)

| Table 2: Positive and negative predictive values of QuantiFERON®-TB Gold results in patients with confirmed TB and patients with other final diagnoses. |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Tuberculosis* | Other final diagnosis* | Positive predictive value | Negative predictive value |
|----------------|----------------------|---------------------------|---------------------------|
| **All patients; n = 141** | | | | |
| QFT-G positive | 41 | 16 | 71.9% | 67.6% |
| QFT-G negative | 24 | 50 | 61.1% | 67.7% |
| QFT-G indeterminate | 5 | 5 | 90.5% | 66.7% |
| **Suspected pulmonary TB; n = 104** | | | | |
| QFT-G positive | 22 | 14 | 61.1% | 67.7% |
| QFT-G negative | 20 | 42 | 90.5% | 66.7% |
| QFT-G indeterminate | 2 | 4 | 90.5% | 66.7% |
| **Suspected extrapulmonary TB; n = 37** | | | | |
| QFT-G positive | 19 | 2 | 90.5% | 66.7% |
| QFT-G negative | 4 | 8 | 90.5% | 66.7% |
| QFT-G indeterminate | 3 | 1 | 90.5% | 66.7% |

QFT-G: QuantiFERON®-TB Gold; TST: Tuberculin skin test
* Bacteriological and/or clinical diagnosis
Immigrants from high and intermediate prevalence countries – comparison of QFT-G results among patients with tuberculosis and healthy controls

The TB incidence in the country of origin was lower among the 98 immigrant controls than for the 52 patients who originated from high and intermediate prevalence regions (mean 63 vs. 158 new cases/100 000 inhabitants; \( P < 0.001 \)). The mean age of the control subjects was lower than that of the immigrant patients (31.8 years vs. 42.6; \( P < 0.001 \)) and the male/female ratio was higher (63/35 vs. 41/42). The most common countries of origin were Iraq (58), the Palestine (11) and Somalia (7) for the immigrant controls, and Serbia (9), Somalia (9), Bosnia-Herzegovina (8), Iraq (8) and Afghanistan (8) for the immigrant patients.

Among the 52 immigrant patients with confirmed TB, 33 (63.5%) had positive QFT-G results. QFT-G results could be determined in 96 of 98 controls. Among these, 10 (10.4%) had a positive result. In control subjects with TST results, the induration was \( \geq \)10 mm in 39 of 85 (45.9%) persons.

When comparing subjects from high-prevalence countries, the PPV for a positive QFT-G in patients with active TB was 76.7%, and the NPV was 82.7%. The corresponding PPV and NPV for a TST with cut off of 10 mm was 44.3% and 93.9% respectively (Table 3). In terms of sensitivity and specificity the results were for QFT-G 67.3% and 89.6% respectively (McNemar test for overall accuracy: \( P = 0.327 \)) and for TST 91.2% and 54.1% respectively (McNemar test: \( P < 0.001 \)).

Factors associated with QFT-G result in patients with active tuberculosis

To further explore factors that may influence the QFT-G results in TB-patients, various parameters were tested. The findings are divided with regard to the variable’s quality (dichotomous or scale) and are presented in Table 4 and 5. Positive QFT-G results were more common in patients with extrapulmonary TB than in those with pulmonary disease. The concentration of INF-\( \gamma \) was also significantly higher in patients with extrapulmonary symptoms compared to patients with pulmonary symptoms (mean 11.3 IU/mL vs. 1.9 IU/mL; Student’s t-test: \( P < 0.001 \)). The difference between women and men was borderline significant, with a higher likelihood of positive results in women (OR 2.70; 95% CI: 0.96–7.62; \( P = 0.0504 \)).

Table 3: Comparison of QFT-G and TST results in TB patients and controls with origin from country with intermediate or high TB incidence (n = 150).

|                | TB-patients* | Controls | Positive predictive value | Negative predictive value |
|----------------|--------------|----------|---------------------------|---------------------------|
| QFT-G positive | 33           | 10       | 76.7%                     | 84.3%                     |
| QFT-G negative | 16           | 86       |                           |                           |
| QFT-G indeterminate | 3          | 2        |                           |                           |
| TST \( \geq \) 10 mm | 31       | 39       | 44.3%                     | 93.9%                     |
| TST <10 mm     | 3            | 46       |                           |                           |
| TST not performed | 18       | 13       |                           |                           |

QFT-G: QuantiFERON®-TB Gold; TST: Tuberculin skin test
* Bacteriological and/or clinical diagnosis

In order to account for confounding factors, parameters that may influence the QFT-G result were entered into a logistic regression model (Table 6). After controlling for sex and a diagnosis of extrapulmonary TB, the only significant difference was a lower WBC in QFT-G positive individuals.

Antigens for incubation experiments

The antigens added for incubation experiments, TB7.7 and PPD, did not show a significant effect on the results. Six positive QFT-G tests based on TB7.7 only were noted, 2 each in the TB patient group, the non-TB patient group and the group of healthy immigrants. QFT-PPD was used for experiments only and did not give rise to positive QFT-G results alone. The correlation between QFT-PPD and TST was 0.232 (Pearson’s correlation test; \( P = 0.075 \)). In TB patients there was a significant, negative correlation between WBC and QFT-PPD (-3.178; Pearson’s correlation test; \( P = 0.003 \)).
Correct diagnosis of tuberculosis remains a challenge in clinical practice, especially for extrapulmonary disease manifestations for which invasive procedures are required to detect mycobacteria in affected tissues. In this study, performed among patients investigated for suspected TB in a low-prevalence region, the overall usefulness of QFT-G as part of the initial diagnostic procedure was limited, with a low negative predictive value for identifying active TB. Interestingly, we observed that a negative QFT-G reaction was more common in pulmonary TB than among patients with extrapulmonary disease manifestations. Among patients with extrapulmonary TB, QFT-G performed much better. Most patients with extrapulmonary TB in our material had isolated peripheral lymphadenitis. Lymph node biopsies were obtained in several of these patients, and showed pronounced granulomatous inflammatory reaction; in addition, the mycobacterial load was low, since bacterial growth was only detected from biopsies and not in fine-needle aspirates. Such a presentation is common in peripheral tuberculous lymphadenitis in HIV-negative patients, and is related to a strong immune response [21], further supported by the finding of high IFN-γ secretion in such patients [22,23].

Our results on the PPV and NPV of IGRA in active TB are in agreement with those reported by others [10,13,24,25]. The limited sensitivity of IGRA tests in active TB could be related to the secretion of IFN-γ suppressive factors in active TB [26], or to the immunological capacity of the host to contain mycobacterial replication [23]. IFN-γ secretion has been shown to be inversely correlated to disease severity in patients with TB [23,27,28]. Lower rates of IFN-γ secretion and higher frequencies of indeterminate IGRA results have also been observed in HIV-infected subjects [29-31]. We did not find any correlation with QFT-G results and the presence of immunosuppression in our patients; however, the proportion of HIV-infected subjects

### Table 4: Dichotomous variables; association with QFT-G results in tuberculosis patients

| Variable                                | QFT positive | QFT negative | Odds ratio (95% CI) | p-value |
|-----------------------------------------|--------------|--------------|---------------------|---------|
| Male                                    | 14           | 14           | 2.70 (0.96–7.62)    | 0.0504  |
| Female                                  | 27           | 10           |                     |         |
| Origin from high or intermediate TB incidence country | 33           | 16           | 2.04 (0.63–6.66)    | 0.1710  |
| Origin from low incidence country       | 8            | 8            |                     |         |
| Born abroad and lived <5 years in Sweden | 14           | 5            | 1.95 (0.61–6.96)    | 0.1970  |
| Born in, or lived >5 years in Sweden    | 27           | 19           |                     |         |
| Extra pulmonary tuberculosis            | 19           | 4            | 4.31 (1.25–14.87)   | 0.0142  |
| Pulmonary tuberculosis                  | 22           | 20           |                     |         |
| Sputum smear negative                   | 9            | 6            | 1.62 (0.38–7.15)    | 0.4666  |
| Sputum smear positive                   | 13           | 14           |                     |         |
| Immunosuppressed patients               | 9            | 8            | 1.76 (0.55–5.58)    | 0.2357  |
| Immune-competent patients               | 32           | 16           |                     |         |
| TST ≥ 10 mm                             | 27           | 9            | 3.00 (0.37–24.50)   | 0.3000  |
| TST < 10 mm                             | 2            | 2            |                     |         |

QFT: QuantiFERON®-TB Gold; CI: Confidence Interval; BMI: Body Mass Index (kg/m²); TST: Tuberculin skin test

5 patients with indeterminate results excluded

* High or moderate TB-incidence is defined as ≥20 cases/100 000 population

** For pulmonary TB only (result missing in 2 patients)

*** Immune suppression defined as HIV-infection, ongoing immunosuppressive treatment, cancer, diabetes, alcohol or drug abuse

### Table 5: Means of scale variables and their association with QFT result in TB patients

| Variable                                | Number of observations | QFT positive | QFT negative | 95% CI of difference | t-test | p-value |
|-----------------------------------------|------------------------|--------------|--------------|----------------------|--------|---------|
| Age (years)                             | 65                     | 42           | 44           | -12.4–7.9            | -0.45  | 0.657   |
| TB incidence of native country (new cases/100 000 pop.) | 65                     | 133          | 87           | -17.7–11.0           | 1.45   | 0.157   |
| Body Mass Index (BMI)                   | 58                     | 22.7         | 20.7         | 0.1–4.0              | 2.08   | 0.043*  |
| Hemoglobin (Hb; g/L)                    | 59                     | 125          | 121          | -0.7–14.3            | 1.01   | 0.315   |
| ESR (mm)                                | 41                     | 45           | 56           | -31.5–9.2            | -1.12  | 0.272   |
| C-reactive protein (CRP; mg/L)          | 59                     | 42           | 79           | -76.9–2.4            | -1.91  | 0.065   |
| Total leukocyte count (cells × 10⁹/L)   | 60                     | 5.9          | 8.8          | -4.3–1.4             | -4.02  | <0.001* |
| TST (mm)                                | 40                     | 23           | 15           | 1.2–15.4             | 2.40   | 0.025*  |

* Significant difference of means
Table 6: Multiple logistic regression analysis of factors potentially associated with QFT-results in TB-patients (after controlling for sex and extrapulmonary TB)

| Factor                                   | Number of observations | Est. beta-coefficient | OR* | 95% CI          | p-value
|------------------------------------------|------------------------|-----------------------|-----|-----------------|--------
| Bacteriologically verified diagnosis     | 65                     | -0.022                | 0.98| 0.20–4.78       | 0.977  |
| TST cut off 10 mm                        | 40                     | -0.666                | 0.51| 0.21–1.28       | 0.153  |
| TST cut off 15 mm                        | 40                     | 1.384                 | 3.99| 0.72–22.15      | 0.114  |
| Immune suppression***                    | 65                     | -0.680                | 0.51| 0.15–1.76       | 0.284  |
| TB incidence of native country (new cases/100 000 pop.) | 65                     | 0.003                 |    | 0.200          |        |
| Body Mass Index (BMI)                    | 58                     | 0.146                 |    | 0.110          |        |
| Hemoglobin (mg/L)                        | 59                     | 0.022                 |    | 0.181          |        |
| Erythrocyte Sedimentation Rate (mm)      | 41                     | -0.005                |    | 0.995          |        |
| C-reactive protein (CRP;mg/L)            | 59                     | -0.007                |    | 0.124          |        |
| White blood cell count (WBC; × 10^9/L)   | 60                     | -0.568                |    | <0.001         |        |

*Odds ratios (defined as the exponent of the estimated beta) are not shown for TB incidence of native country, BMI, Hb, ESR, CRP and WBC since these variables are not dichotomous.

** Immune suppression defined as HIV-infection, ongoing immunosuppressive treatment, cancer, diabetes, alcohol or drug abuse

in our material was rather low. For T-SPOT®. TB, indeterminate results have been associated with delayed handling times [32], whereas an evaluation of cytokine techniques under different circumstances found that ELISA performance was not much affected by handling conditions [33]. The rate of indeterminate results was 7.1% (10/141) in this study, which is at the same level as reported in other studies on patients with suspected clinically active TB disease [34]. The rate of false negative was 34% in this study (24/70). There are large variations in the literature but several other studies have reported a similar low sensitivity in patients with active tuberculosis [10,13,35,36]. In our study, all samples were sent to the laboratory and processed within 7 hours; thus, it is unlikely that technical problems explain the high frequency of negative and indeterminate results in patients with confirmed active TB.

It has been suggested to lower the cut-off limits for the IGRA tests in low incidence settings in order to improve sensitivity[37]. Recalculating PPV and NPV in our material using the cut-off limits 0.20 IU/mL and 0.10 IU/mL reduced PPV for patients with pulmonary and extrapulmonary TB respectively. Only the lowest cut-off limit raised the NPV slightly (data not shown). Hence, lowering cut-off limits for the QFT-G would not benefit the test’s performance in our setting.

The magnitude and characteristics of immune response are important factors for the pathogenesis and disease manifestations in tuberculosis, and they are likely to be associated with the rate of IFN-γ secretion. A parallel may be drawn to leprosy, another mycobacterial infection in which the immune response is critical for disease presentation. In an Indian study, significantly higher IFN-γ secretion was detected in patients with tuberculoid variants of leprosy, as opposed to lepromatous forms (in which the Th-1 response is weak) [38]. The association between WBC in peripheral blood and QFT-G outcome in our TB patients could be a reflection of the same phenomenon, and are in agreement with findings reported by Shang and co-workers, showing enhanced peripheral blood leukocytosis in mice with targeted mutation of chemokine receptor 1 and reduced IFN-γ secretion [39]. The lower BMI in QFT-G negative TB-patients is also likely to be related to a reduced capacity for INF-γ secretion in patients with advanced disease.

When assessing the usefulness of IGRA testing for detecting active TB, the immunological profile of the studied patients should thus be taken into account. Our results may not be applicable for HIV-positive patients. Furthermore, several IGRA techniques have been developed, and in a meta-analysis of commercially available IGRA:s differences with regard to sensitivity and applicability have been found [6,16]. We used an extended, in-house variant of QuantiFERON®-TB Gold, with the addition of another MTB specific antigen (TB7.7) apart from those included in the commercial kit. However, the inclusion of this antigen did not appear to affect test outcome. In this study, we did not appear to affect test outcome. In this study, we have not compared the two different IGRA test methods. Although comparisons between QFT-G and T-SPOT®. TB suggest that the latter may be more sensitive for diagnosing latent TB, the significance of this difference in clinical practice is not clear. Furthermore, QFT has the advantage of being easier and less expensive to perform than T-SPOT®. TB testing. Both IGRA test methods have superior specificity for TB compared to TST, but sensitivity is probably lower (depending on the TST cut-off chosen to define TB infection). However, in analogy with QFT-G, false negative TST reactions are common in severe forms of TB [40].

An important finding from our study is that QFT-G had similar positive and negative predictive values for active TB among native Swedes and immigrants from high-prev-
alence countries – a group that presently constitutes the majority of TB patients in Sweden as well as in most other European countries. This is somewhat surprising in view of the limited sensitivity of QFT-G for active TB, and the presumed high prevalence of latent TB among the healthy immigrant controls (TST ≥ 10 mm in 39/85, 46%). With regard to the fact that the incidence of TB in the countries of origin among immigrant patients was higher than in controls, it may be anticipated that the exposure to TB was different between these groups. Still, this observation raises further questions regarding the significance of QFT-G and TST for identification of persons infected with M. tuberculosis.

Conclusion
The overall usefulness of QFT-G for identifying active TB was limited among patients investigated for suspected TB in a typical setting in a North-European low-prevalence region. Poor performance was more common in patients with pulmonary disease, whereas the PPV for QFT-G was satisfactory among patients with extrapulmonary disease manifestations. Since TB is more difficult to diagnose in such cases, we suggest that it may be reasonable to consider QFT-G for screening patients with suspected extrapulmonary TB. Furthermore, the PPV and NPV of QFT-G for detection of active TB among immigrants from high and intermediate prevalence regions seem to be similar to that observed in non-immigrants.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
NW, PB and HM were responsible for planning the study, analyzing the results and drafting the manuscript. HM designed the antigen panel used for QFT-G testing. NW, AN and PB collected the study material and coordinated the study. All authors have read and approved the manuscript.

Acknowledgements
Skane county council’s research and development foundation and the Swedish Heart-Lung Foundation supported the study financially. We would like to acknowledge all doctors and nurses at the participating departments of infectious and pulmonary diseases in the university hospitals in Malmö and Lund for their involvement in patient enrollment and specimen collection. Special thanks also to Arne Forsgren, Department of laboratory medicine, Malmö, Lund University, for help in planning the study, Annica Andreasson at Clinical microbiology and immunology, Lund university hospital, Lund for performing the QFT-G test and Häkan Lövkvist at Competence Centre for Clinical Research, Lund for statistical assistance.

References
1. Lalvani A, Pathan AA, Durkan H, Wilkinson KA, Whelan A, Deeks JJ, Reece WH, Gold M, Parsoni G, Hill AV: Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001, 357(9273):2017-2021.
2. Ravn P, Munk ME, Andersen AB, Lundgren B, Nielsen LN, Lillebaek T, Soerensen IJ, Andersen P, Wedlingh K: Reactivation of tuberculosis during immunosuppressive treatment in a patient with a positive QuantiFERON-RD1 test. Scandinavian journal of infectious diseases 2004, 36(6–7):499-501.
3. Fietta A, Meloni F, Cescia A, Morosini M, Marena C, Trupiotti P, Mangiarotti P, Casali L: Comparison of a whole-blood interferon-gamma assay and tuberculin skin testing in patients with active tuberculosis and individuals at high or low risk of Mycobacterium tuberculosis infection. American journal of infection control 2003, 31(6):347-353.
4. Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T: Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis 2005, 24(8):529-536.
5. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawai Y, Nagao K, Shigeto E, Harada N, Mitarai S, Okada M, et al: Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. American journal of respiratory and critical care medicine 2007, 170(1):59-64.
6. Pai M, Zwerling A, Menzies D: Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Annals of internal medicine 2008, 149(3):177-184.
7. Wang L, Turner MO, Elwood RK, Schulzer M, FritzGerald JM: A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002, 57(9):804-809.
8. Bloom BR, Small PM: The evolving relation between humans and Mycobacterium tuberculosis. The New England Journal of medicine 1998, 338(10):677-678.
9. Boussiotis VA, Tsai EY, Yunis EJ, Thim S, Delgado JC, Dascher CC, Berezovskaya A, Rousset D, Reves RR, Toney SR, Daniels LJ, LoBue PA: Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection with Mycobacterium tuberculosis: a prospective study. J Infect Dis 2006, 367(9519):1328-1334.
10. Pai M, D’Amico R, Roovers P, Piro R, Peacci M, Meccugi B, Dori IM, Andreani A, Bergmin BM, et al: Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006, 367(9519):1328-1334.
11. Menzies D, Pai M, Zwerling A, Menzies D: Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Annals of internal medicine 2007, 146(5):340-354.
12. Kan B, Berggren I, Ghebremichael S, Bennet R, Bruchfeld J, Chrysanthou E, Kallenius G, Petersson R, Petriini B, Romanus V, et al: Extensive transmission of an isoniazid-resistant strain of Mycobacterium tuberculosis in Sweden. Int J Tuberc Lung Dis 2008, 12(2):199-204.
13. Winquist N, Andersen PH, Lillebaek T, Bjorkman P, Mironier H: Demographics of tuberculosis in an emerging EU region in southern Scandinavia. Scandinavian journal of infectious diseases 2006, 38(11–12):1033-1039.
14. Welfare TNBoHa: Case definitions on report in accordance with the Swedish Disease Control and Prevention Act. Welfare TNBoHa: The National Board of Health and Welfare; 2008.
15. Global tuberculosis control – surveillance, planning, financing [http://www.who.int/tb/publications/global_report/2008/en/]

Page 8 of 9 (page number not for citation purposes)
21. Polesky A, Grove W, Bhatia G: Peripheral tuberculous lymphad- enitis: epidemiology, diagnosis, treatment, and outcome. Medicine 2002, 81(3):150-362.

22. Habe A, Geletu M, Olobo JO, Kidane D, Negesse Y, Yassin MA, Kifle B, Abate G, Harboe M, Aseff A: T cell mediated immune responses in patients with tuberculous lymphadenitis from Butajira, southern Ethiopia. Ethiopian medical journal 2004, 42(Suppl 1):29-35.

23. Pathan AA, Wilkinson KA, Klerkenman P, McShane H, Davidson RN, Pasvol G, Hill AV, Lalvani A: Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001, 167(9):5217-5225.

24. Dewan PK, Grindsdale J, Kawamura LM: Low sensitivity of a whole-blood interferon-gamma release assay for detection of active tuberculosis. Clin Infect Dis 2007, 44(1):69-73.

25. Pai RK, Convery M, Hamilton TA, Boom WH, Harding CV: Inhibition of IFN-gamma-induced class II transactivator expression by a 19-kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasion. J Immunol 2003, 171(1):175-184.

26. Goletti D, Butera G, Bizzoni F, Caserti R, Girardi E, Poccia F: Region of difference 1 antigen-specific CD4+ memory T cells correlate with a favorable outcome of tuberculosis. The Journal of infectious diseases 2006, 194(7):984-992.

27. Sodhi A, Gong J, Silva C, Qian D, Barnes PF: Clinical correlates of interferon gamma production in patients with tuberculosis. Clin Infect Dis 1997, 25(3):617-620.

28. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P: Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respiratory research 2006, 7:36.

29. Low sensitivity of a whole-blood interferon-gamma release assay for detection of active tuberculosis. Clin Infect Dis 2007, 44(1):69-73.

30. Pathan AA, Wilkinson KA, Klerkenman P, McShane H, Davidson RN, Pasvol G, Hill AV, Lalvani A: Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001, 167(9):5217-5225.

31. Pathan AA, Wilkinson KA, Klerkenman P, McShane H, Davidson RN, Pasvol G, Hill AV, Lalvani A: Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001, 167(9):5217-5225.

32. Pathan AA, Wilkinson KA, Klerkenman P, McShane H, Davidson RN, Pasvol G, Hill AV, Lalvani A: Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001, 167(9):5217-5225.

33. Pathan AA, Wilkinson KA, Klerkenman P, McShane H, Davidson RN, Pasvol G, Hill AV, Lalvani A: Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001, 167(9):5217-5225.

34. Pathan AA, Wilkinson KA, Klerkenman P, McShane H, Davidson RN, Pasvol G, Hill AV, Lalvani A: Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001, 167(9):5217-5225.

35. Pathan AA, Wilkinson KA, Klerkenman P, McShane H, Davidson RN, Pasvol G, Hill AV, Lalvani A: Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001, 167(9):5217-5225.